Description
Creative Biolabs enhances the binding ability of the anti-EGFR antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the antibody.
Applications
Increase the half-life of antibodies
Technology
Fc engineering technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EGFR antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
epidermal growth factor receptor
Background
EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Antibody Clone
AES-0622-ZP1001
Description
Creative Biolabs enhances the binding ability of the anti-EGFR antibody to FcRn by modifying the Fc of the antibody, thereby increasing the half-life of the anti- antibody.
